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A series of 7 new human/rat Corticotropin Releasing Hormone (h/r-CRH) analogues were synthesized. The induced alterations
include substitution of Phe at position 12 with D-Phe, Leu at positions 14 and 15 with Aib and Met at positions 21 and 38 with
Cys(Et) and Cys(Pr). The analogues were tested regarding their binding aﬃnity to the CRH-1 receptor and their activity which
is represented by means of percentage of maximum response in comparison to the native molecule. The results indicated that
the introduction of Aib, or Cys derivatives although altering the secondary structure of the molecule, did not hinder receptor
recognition and binding.
1.Introduction
Ever since its identiﬁcation by Vale et al. [1], Corticotropin
Releasing Hormone (CRH) has proven to be a major
neuromodulator responsible not only for the secretion of
ACTH by the anterior pituitary gland but also for the
regulation of the endocrine, autonomic, immunological and
behavioral responses to stress [2–4]. Furthermore, this 41-
amino acid neuropeptide displays a plethora of additional
roles in either physiological homeostasis or pathogenic
manifestationsvaryingfromthewell-establishedimplication
on neuropsychiatric disorders [5, 6] to the yet to be clariﬁed
actions on various forms of cardiovascular diseases [7]
obesity [8] or gut motility [9], among others. A series of
studies demonstrating the extent and perplexity of the roles
and implications of CRH led to the identiﬁcation of other
peptides appearing to possess a similar role [10–13].
Both the isolation and characterization of the CRH
family receptors has been achieved revealing two receptor
subtypes, one of them appearing as three splice variants
(CRH-R1, CRH-R2α, CRH-R2β, and CRH-R2γ). A binding
protein (CRH-BP) was also described [14–18].The most-
studied receptor types are CRH-R1, CRH-R2α, and CRH-
R2β not only due to their vast distribution but also for
their implication in physiological functions or disorders
of great importance. CRH-R1 is broadly distributed in
the brain and the pituitary gland but also appears in a
number of peripheral tissues [19]. It possesses a critical
role in mediating the hypophysiotropic action of CRH
[20] but furthermore is involved in anxiogenic behaviours,
depression and anxiety [21], anorexia and bulimia, drug
seeking and withdrawal, and seizure [22, 23]. CRH-R2α
is mainly a brain receptor whereas CRH-R2β is largely
expressed in the periphery. The role of CRH-R2 is more
diverse since it extends from “stress-coping” responses
(anxiolysis, hypotension) to gastric emptying, regulation of
energy expenditure, anti-inﬂammatory, and other actions of
CRH [24]. However, further and complete understanding
of the hormone-receptor interaction on its chemical basis
is essential mainly since it can provide a solid basis for the
development of CRH analogues with potent therapeutical
implications.2 Bioinorganic Chemistry and Applications
TwodistinctcategoriesofCRHreceptorligands(ofeither
agonistic or antagonistic character) have been developed,
namely, peptide and nonpeptide ligands. The latter are
unambiguously a large and diverse family but only few of
these small molecules entered clinical development and still
none of them found its way to the market [25]. The former
category is more likely to yield clear information regarding
the interaction between the peptide and its receptor.
Towards this goal, extensive SAR studies have been
carriedout.Singleaminoacidmodiﬁcationstudiesidentiﬁed
the key regions of the peptide for agonist/antagonist proper-
ties as well as for the receptor binding aﬃnity. Based on these
studies, theassignment of themolecule’ssecondary structure
was feasible leading to the establishment of an α-helical
structure (showing high amphiphilicity) for CRH-related
peptides as the preferred conformation [9]. Notably, the
helical nature of the molecule varies from 20% in solution
to 80% upon binding [26].
A hypothesis was that stabilization of the α-helix
could aﬀect positively the activity of either agonists or
antagonists. Subsequent studies aﬃrmed this conjecture
establishing that conformationally restrained analogues
present increased potency. In addition, modiﬁcations on
hydrophilicity/hydrophobicity or acidity/basicity of some
residues were crucial in altering the potency of an analogue
[26].
Introduction of D-amino acids leading to stabilization
of β-turns, can provide analogues with increased potency
but not all residues are susceptible to such an alteration,
leading even to the opposite eﬀect. However, the D-Phe12
substitution has proven to be a favorable one especially
combinedwithotheradvantageousmodiﬁcationssuchasthe
replacement of Met at positions 21 and 38 with Nle. Thus, it
has been shown that [D-Phe12]CRH is twice as potent and
[D-Phe12,N l e 21,38]CRH21−41 is 15 times more potent than α-
helical CRH [26].
The present study presents the synthesis of 7 new h/r-
CRH analogues bearing minor modiﬁcations on the key
amino acids side chain, regarding their electrochemical
nature (Table 1). Speciﬁcally, we discuss the replacement of
Leu at positions 14 and 15 with α-Aminoisobutyric acid
(Aib), which apart from introducing a bend in the peptide
backbonecanstabilizethea-helixstructure[27,28],andalso
the replacement of Met at positions 21 and 38. The amino
acids used for the latter modiﬁcation are Cysteine(Ethyl)
[Cys(Et)], an isoster of Met and Cysteine(Propyl) [Cys(Pr)]
that possesses a slightly more hydrophobic side chain than
Cys(Et). The analogues were tested regarding their ability to
induce the formation of intracellular cAMP in comparison
to natural CRH measured by means of luciferase activity.
2. Experimental
2.1. Materials. 2-chlorotrityl-chloride resin bearing a
Rink-Bernatowitz linker and 9-Fluorenylmethoxycarbonyl
(Fmoc)-protected amino acids were supplied by CBL
Patras. All solvents and reagents used for solid-phase
peptide synthesis were purchased from Bachem AG and
Novabiochem and were used without further puriﬁcation
being of analytical quality. Nonnatural amino acid
derivatives Cysteine (Ethyl) [Cys(Et)] and Cysteine (Propyl)
[Cys(Pr)] were prepared according to literature [29].
2.2. Peptide Synthesis and Puriﬁcation. Synthesis of the
analogues was performed via Fmoc solid phase methodology
[30] utilizing either Rink Amide MBHA resin [31]o r2 -
chlorotrityl-chloride resin [32] bearing a Rink-Bernatowitz
linker [33] to provide the peptide amide. The side-chain
protection used for the Fmoc-protected amino acids was
the trityl group (Trt) for His, Asn, and Gln, the tert-butyl
group (But) for Asp, Tyr, Glu, Ser and Thr, the tert-
butyloxy-carbonyl group (Boc) for Lys and the 2,2,4,6,7-
pentamethyl-dihydrobenzofuran-5-sulphonyl group (Pbf)
for Arg. Stepwise synthesis of the peptide analogues was
preferred to convergent synthesis due to the lack of Gly
or Pro moieties at convenient positions in the amino acid
sequence. The amino acids were coupled at three-fold
excess using diisopropylcarbodiimide/1-hydroxybenzotria-
zole (DIC/HOBt) [34, 35] in Dimethylformamide (DMF)
and, if necessary, 2-(1H-benzotriazole-1-yil)-1,1,3,3-te-
tramethyluroniumhexaﬂuorophosphate (TBTU)/HOBt/di-
isopropyl ethylamine (DIEA) in DMF [36]. After 2 hours
coupling time at room temperature, the ninhydrin test
[37] was performed to estimate the completeness of
the reaction with the exception of coupling on a Pro
residue where the Chloranil test was employed to conﬁrm
reaction’s completion point [38]. Fmoc groups were
removed by treatment with 20% piperidine in DMF for
5 minutes followed by a prolonged treatment with the
same solution for 20 minutes to ensure complete removal.
The ﬁnal cleavage of the peptide from the solid support
together with the removal of the side-chain protecting
groups was accomplished by treatment with a solution
(15mL/g peptide resin) of triﬂuoroacetic acid (TFA)/1,2-
ethanedithiol/anisole/triethylsilane/water (94:2.5:0.5:1.5:
1.5,v/v)for4hoursatroomtemperature.Theobtainedmix-
ture underwent solvent evaporation followed by anhydrous
ethyl ether precipitation to yield the ﬁnal crude peptide.
All the products were puriﬁed by gel ﬁltration chro-
matography on Sephadex G-25 (ﬁne) using 25% acetic acid
as eluent. Final puriﬁcation was achieved by preparative high
performance liquid chromatography (HPLC, Pharmacia
LKB-2250) on reversed-phase support C-18 with a linear
gradient from 30 to 85% acetonitrile (0.1% TFA) for 35
minutes at a ﬂow rate 1.5 mL/min and UV detection at
230 and 254nm. The appropriate fractions were pooled
and lyophilized. Analytical HPLC (Pharmacia LKB-2210)
equipped with a Nucleosil 100 C18 column (5μmp a r t i c l e
size;250×4.6mm)producedsinglepeakswithatleast98%of
the total peptide peak integrals. The solvent system used was
the same as that for the semipreparative HPLC. All products
gave single spots on thin layer chromatography (TLC, Merck
precoated silica gel plates, type G60-F254) in the solvent sys-
tems: (A) 1-butanol: acetic acid: water (4:1:5, upper phase)
and (B) 1-butanol: acetic acid: water: pyridine (15:3:10:6).
The ﬁnal characterization of the peptide sequence wasBioinorganic Chemistry and Applications 3
Table 1: Structure of synthesized CRH analogues.
Human/Rat CRH Analogue 1 Analogue 2 Analogue 3 Analogue 4 Analogue 5 Analogue 6 Analogue 7
1S
2E
3E
4P
5P
6I
7S
8L
9D
10 L
11 T
12 E D-phe D-phe D-phe D-phe D-phe D-phe D-phe
13 H
14 L Aib
15 L Aib
16 R
17 E
18 V
19 L
20 E
21 M Cys(Et) Cys(Et) Cys(Pr) Cys(Pr)
22 A
23 R
24 A
25 E
26 Q
27 L
28 A
29 Q
30 Q
31 A
32 H
33 S
34 N
35 R
36 K
37 L
38 M Cys(Pr) Cys(Pr) Cys(Et) Cys(Pr)
39 E
40 I
41 I
achieved by Electrospray Ionisation-Mass Spectrometry
(ESI-MS, Micromass-Platform LC instrument). An example
of analytical HPLC-chromatograms and ESI-MS spectrum
are shown in Figure 1 for analogue 7. The physiochemical
properties of the new analogues are summarized in Table 2.
2.3. Biological Assays. The capacity of CRH and related
peptide analogues to stimulate cyclic AMP generation was
monitored in LLC-PK1 cells cotransfected with cDNA of
CRH-R1 and CRE. For transfection the method of electro-
poration was applied and 40 millions of LLC-PK1 cells were
prepared and washed in cytomix 1X transfection medium.
Theelectroporationmediumconsistedof1000μLofcytomix
2X, 864μL of sterilized water, 80μL of ATP 50mM, 3.2mg
of glutathion, 20μg of CRH-R1 cDNA and 20μgo fC R E
cDNA. 500μL of the above solution were transferred in the
electroporation device and after remaining for 10 minutes
a standard growth medium was added (DMEM without4 Bioinorganic Chemistry and Applications
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Figure 1: (a) Analytical HPLC chromatogram of crude analogue [D-Phe12, Cys(Pr)21, Cys(Pr)38]CRH previously chromatographed on a
semipreparativeC18column.(b)AnalyticalHPLCchromatogramofanalogue[D-Phe12,Cys(Pr)21,Cys(Pr)38]CRHuponrechromatography
on the same column. (c) Mass spectra of analogue [D-Phe12, Cys(Pr)21, Cys(Pr)38]CRH resulting from ESI-MS analysis [MWcalc = 4785.58;
(M+4)obs
4+/4=1198.2; (M+ 3)obs
3+/3=1596.5].
Table 2: Physicochemical properties of h/r-CRH analogues used in the present study.
Analogues Yield
a HPLC
b TLC, Rf
c
(%) tR (min) A B
1[ D - P h e 12,A i b 14]CRH 41 22.79 0.22 0.39
2[ D - P h e 12,A i b 15]CRH 38 22.85 0.21 0.38
3[ D - P h e 12,Cys(Et)21]CRH 39 23.05 0.19 0.37
4[ D - P h e 12,Cys(Pr)38]CRH 37 23.28 0.20 0.36
5[ D - P h e 12,Cys(Et)21, Cys(Pr)38]CRH 33 24.07 0.18 0.35
6[ D - P h e 12,Cys(Pr)21,C y s ( E t ) 38]CRH 35 23.99 0.17 0.33
7[ D - P h e 12,Cys(Pr)21, Cys(Pr)38]CRH 36 24.32 0.17 0.34
aYields were calculated on the basis of the amino acid content of the resin. All peptides were at least 98% pure.
bFor elution conditions, see the Experimental Section.
cSolvent systems and conditions are reported in the Experimental Section.
phenol red with glutamine, antibiotics, and 10% FCS) to
a total volume of 50mL. The suspension was distributed
in 8 plates of 24 wells each, by adding 1mL per well,
and was allowed to pre-incubate for 24 hours. The growth
medium was aspirated and replaced with fresh one followed
by another preincubation for 24 hours. The cells were then
challenged with graded concentrations (10−6 to 10−11 M) of
the test peptides and incubated for 7 hours at 37◦C. After
that, the medium with the added peptides was removed,
the cells were washed twice with PBS 1X, 100μLo fl y s i s
buﬀer 1X per well were added, the plates were left at
room temperature for 30 minutes and then stored at −80◦C
overnight. The luciferace activity was measured with the use
of a luminometer after the addition of 50μLo fl y s e dc e l l
preparation and 50μL of bioluminescence medium per well
in a 96 well plate luminometer.
3. Results
3.1. Peptide Synthesis and Puriﬁcation. All analogues shown
in Table 2 were synthesized either manually or automaticallyBioinorganic Chemistry and Applications 5
Table 3: Binding aﬃnities of h/r-CRH analogues.
Analogues Binding aﬃnity
aIC50 (nM)
h/r-CRH 17.3
1[ D - P h e 12,A i b 14]CRH 226
2[ D - P h e 12,A i b 15]CRH 8.4
3[ D - P h e 12,C y s ( E t ) 21]CRH 28.5
4[ D - P h e 12, Cys(Pr)38]CRH 35
5[ D - P h e 12,C y s ( E t ) 21, Cys(Pr)38]CRH 7.0
6[ D - P h e 12, Cys(Pr)21,C y s ( E t ) 38]CRH 3.4
7[ D - P h e 12, Cys(Pr)21, Cys(Pr)38]CRH 17.3
aThe values given are averages from 3 experiments performed in duplicates.
Table 4: Biological activity of h/r-CRH analogues.
Analogues Biological activity
h/r-CRH 100% activity (Full agonist)
1[ D - P h e 12,A i b 14]CRH (Partial Agonist, 60% Response max/CRH)
2[ D - P h e 12,A i b 15]CRH (Partial Agonist, 60% Response max/CRH)
3[ D - P h e 12,C y s ( E t ) 21]CRH (Full Agonist, 110% Response max/CRH)
4[ D - P h e 12, Cys(Pr)38]CRH (Partial Agonist, 60% Response max/CRH)
5[ D - P h e 12,Cys(Et)21, Cys(Pr)38]CRH (Partial Agonist, 70% Response max/CRH)
6[ D - P h e 12, Cys(Pr)21,C y s ( E t ) 38]CRH (Partial Agonist, 60% Response max/CRH)
7[ D - P h e 12, Cys(Pr)21, Cys(Pr)38]CRH (Partial Agonist, 80% Response max/CRH)
on the Rink Amide MBHA resin or the 2-chlorotrityl-
chlorideresinbearingaRink-Bernatowitzlinkerassolidsup-
port by using standard coupling procedures and Fmoc/But
strategy. The overall yield of the syntheses of the CRH
analogues was in the range 33–41% (calculated on the
amount of linker initially coupled to the resin). Higher yields
wereobtainedusingtheRinkAmideMBHAassolidsupport.
The synthetic procedure did not present signiﬁcant com-
plications due to the highly helical nature of the analogues
despite the considerable size of the CRH analogues. ESI mass
spectrometry conﬁrmed that the puriﬁed products were
indeed the desired peptides and analytical HPLC revealed a
purity of over than 98% for the synthetic analogues.
3.2. Biological Activity. The results of the biological evalua-
tion regarding the synthesized analogues are set out in Tables
3 and 4.T h eI C 50 values (Table 3) indicate a not very wide
but nonetheless notable variety in the aﬃnity to the receptor
for the studied analogues. Speciﬁcally, three of the ana-
logues, namely, [D-Phe12,A i b 15]CRH, [D-Phe12,C y s ( E t ) 21,
Cys(Pr)38]CRH, and [D-Phe12,C y s ( P r ) 21,C y s ( E t ) 38]CRH,
present a higher aﬃnity to the receptor (IC50=8.4nM,
IC50=7.0nMandIC50=3.4nM,resp.)whichisapproximately
2, 2,5, and 5 times that of the natural h/r-CRH (IC50=17.3
nM). [D-Phe12,A i b 14]CRH is the analogue that presents the
higherIC50 value(226nM)indicatingasmalleraﬃnitytothe
receptor, roughly 13 times lower than that of the hormone.
The other three analogues appear to have the same ([D-
Phe12,C y s ( P r ) 21,C y s ( P r ) 38]CRH, IC50=17.3nM) or slightly
reduced ([D-Phe12,C y s ( E t ) 21]CRH, IC50=28.5nM and [D-
Phe12,C y s ( P r ) 38]CRH, IC50=35.0nM) aﬃnity compared to
CRH.
Regarding the activity of the analogues which is repre-
sented by means of percentage of maximum response com-
pared to that of h/r-CRH (Table 4), the only analogue that
presents a higher percentage is [D-Phe12,C y s ( E t ) 21]CRH
(full agonist, 110% response max/CRH). All other analogues
are partial agonists and induce a maximum response that
varies between 60 and 80 per cent of the maximum response
induced by CRH.
4. Discussion
The design and synthesis of the seven analogues was based
on observations and results already mentioned above and
likely to yield products with desirable properties. D-Phe12
substitutionwasamodiﬁcationpresentinallanaloguessince
it brings only a positive contribution to the potency and
the activity of the analogue. Substitution of Leu at positions
14 and 15 with Aib was based on studies demonstrating
that α-aminoisobutyric acid is a helix-promoter/stabilizer,
which increases the helix propensity of a peptide fragment
towards,eitherα-or3 10-helix,byrestrictionofthebackbone
conformational freedom. Aib, on the other hand, apart from
its tendency to form constrained helices, is also known
for its ability to bend helical peptides. The conformational
features of the analogue [D-Phe12,A i b 15]CRH have already
been studied through 1D and 2D J-correlated 1HNMR
spectroscopy [39].6 Bioinorganic Chemistry and Applications
Biological evaluation of the two Aib containing ana-
logues revealed that they both present the same activity
which is 60 percent that of the natural hormone and thus,
they appear to be partial agonists of CRH. However, when
the IC50 values are taken under consideration, the two
analogues signiﬁcantly vary regarding their aﬃnity to the
receptor. Although the only diﬀerence in their secondary
structure is the position of the Aib moiety (14 or 15)
and furthermore, the two positions are adjacent, [D-Phe12,
Aib15]CRH presents a roughly 27 times higher aﬃnity
than [D-Phe12,A i b 14]CRH. An NMR study of [D-Phe12,
Aib14]CRH and consequent comparison with the results
already extrapolated for [D-Phe12,A i b 15]CRH is the best
means to clarify the eﬀect of the Aib substitution on the
molecule conformation and consequently on its binding
to the receptor. All the same, a primary estimation could
be that the positions 14 and 15 although important for
binding to the receptor might not belong to the region that
is responsible for the hormone’s action since no alteration is
observed on the biological activity for the two analogues.
Cys(Et) and Cys(Pr) are two nonnatural amino acid
residues that have already been used in the synthesis of
peptides (e.g., Angiotensin II) [40] yielding interesting
results. The fact that Cys (S-Et) is an isoster of Met along
with the enhanced potency of the analogues with substituted
Met21 or Met38 were basically taken into account for the
design of the analogues. Cys (S-Pr) was used since it bears
a side-chain that on one hand possesses the S atom present
in Met and on the other hand has a longer aliphatic unit than
Met or Cys(Et). Two of the analogues were monosubstituted
regarding the Met residues, [D-Phe12,C y s ( E t ) 21]CRH, and
[D-Phe12,C y s ( P r ) 38]CRH, and three had a double substi-
tution of Met, [D-Phe12,C y s ( E t ) 21,C y s ( P r ) 38]CRH, [D-
Phe12,C y s ( P r ) 21,C y s ( E t ) 38]CRH and [D-Phe12,C y s ( P r ) 21,
Cys(Pr)38]CRH.
Both[D-Phe12,C ys(Et) 21]CRHand[D-Phe12,C ys(P r) 38]
CRH present reduced aﬃnity to the receptor compared to
CRH, which is approximately half that of the hormone.
Notably, when these modiﬁcations are combined in the
[D-Phe12,C y s ( E t ) 21,C y s ( P r ) 38]CRH analogue, the aﬃnity
appears to enhance signiﬁcantly. However, this combination
does not have the same impact on the activity of the
molecule.[D-Phe12,C ys(Et) 21]CRHistheonlyofthestudied
analogues that presents a higher than CRH activity (110%
that of the hormone) whereas [D-Phe12,C y s ( P r ) 38]CRH
shows reduced activity (60% that of CRH). The activity
of [D-Phe12,C y s ( E t ) 21,C y s ( P r ) 38]CRH, although slightly
higher than that of the latter monosubstituted analogue is
considerably lower than that of the former one. This could
mean that the negative eﬀect of Cys(Pr)38 is more prominent
than the positive one of Cys(Et)21. As for the aﬃnity, no
safe assumptions can be made until further NMR studies are
performed on these molecules.
The results regarding [D-Phe12,C y s ( P r ) 21,C y s ( P r ) 38]
CRH indicate that double substitution with Cys(Pr) does
not aﬀect the aﬃnity of the molecule to the receptor and
decreases only slightly its activity. When the Cys(Pr) residue
is applied at position 38 the IC50 value is negatively aﬀected
and the molecule shows a 40% decrease in activity compared
to CRH. The reversal of this image with the application
of Cys(Pr)21 could be attributed to a positive eﬀect of
this moiety on the molecule but this assumption can be
conﬁrmedonlybythestudyofthe[D-Phe12,C ys(P r) 21]CRH
analogue that remains to be performed.
The analogue presenting the lowest IC50 value is
[D-Phe12,C y s ( P r ) 21,C y s ( E t ) 38]CRH, indicating a 5-fold
increased aﬃnity to the receptor compared to the native hor-
mone and also to the [D-Phe12,C y s ( P r ) 21,C y s ( P r ) 38]CRH.
Regarding the two CRH analogues it could be assumed that
the diﬀerence in aﬃnity is connected with the residue at
position 38, where the Cys(Et) substitution appears to be
more favorable compared to Cys(Pr) substitution.
Considering all the aforementioned remarks, the conclu-
sions are (i) regarding the introduction of Aib, position 15
is preferable to position 14 since it yielded analogues with
higher aﬃnity to the receptor; (ii) although the introduction
of Aib modiﬁes the secondary structure and can alter
signiﬁcantly the aﬃnity to the receptor, the Aib containing
analogues can still be characterised as partial agonists; (iii)
aﬃnity to the receptor and activity do not necessarily
coincide and analogues that excel in the one may fall short
to the other; (iv) simple or combined modiﬁcations with
Cys(Et) or Cys(Pr) in position 21 or/and position 38 did
not hinder receptor recognition leading, in the most of the
cases, to partial agonists with the exception of the ana-
logue [D-Phe12,C y s ( E t ) 21]CRH which presents fullagonistic
activity.
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